The American biotech company Moderna says a candidate’s coronavirus vaccine trial has produced antibodies in elderly patients without serious effects.
Modern’s coronavirus vaccine has shown an immune reaction in elderly patients who participated in an early clinical trial, the biotechnology company announced Wednesday.
The trial involved ten adults over the age of 56 to 70 and ten patients under the age of 70. Each player won two doses of one hundred micrograms of the vaccine 28 days apart.
All the participants produced antibodies and T cells that kill the virus, which serve to strengthen immunity against the disease.
Some patients reported fatigue, chills, headaches and pain at the injection site, but all symptoms disappeared within two days and the company said there were no serious side effects for the vaccine.
Moderna’s shares rose by almost 6% in intraday operations on Wednesday in reaction to the announcement.
Moderna began phase 3 trials of its vaccine last month and hopes to see the effects of the October trials.